# Greenland Mines Ltd: overview GRML · Nasdaq · CIK 1907223 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/grml.md) · [Financials](/companies/grml/financials.md) · [Filings](/companies/grml/filings.md) · [Insiders](/companies/grml/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.18)](/filings/0001213900-25-109920.md) | not reported | [(0.08)](/filings/0001213900-26-090289.md) | [(0.12)](/filings/0001213900-26-090821.md) | [(0.05)](/filings/0001213900-25-109920.md) | not reported | [(0.15)](/filings/0001213900-26-090289.md) | [(0.03)](/filings/0001213900-26-090821.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(0.05)](/filings/0001213900-25-026372.md) | [(0.32)](/filings/0001213900-26-090213.md) | [(0.22)](/filings/0001213900-26-090213.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/grml/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ARISTEIA CAPITAL, L.L.C.](/funds/1080171.md) | 2026-06-30 | $188.2k | 1,106,754 | | Unchanged | | [HIGHBRIDGE CAPITAL MANAGEMENT LLC](/funds/919185.md) | 2026-06-30 | $90.4k | 531,590 | | Reduced −58,410 | | [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $51.0k | 300,000 | | Unchanged | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $20.6k | 120,934 | | Reduced −80,272 | | [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $9.2k | 54,103 | | Added +101 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $5.1k | 30,000 | Call | Unchanged | | [OneDigital Investment Advisors LLC](/funds/1690370.md) | 2026-06-30 | $1.7k | 10,000 | | Unchanged | ## Recent filings [All 267 filings](/companies/grml/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 17:28 ET | [S-1](/filings/0001213900-26-112563.md) | Registration statement | 0001213900-26-112563 | | 2026-10-02 | 16:15 ET | [8-K](/filings/0001213900-26-106394.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-106394 | | 2026-09-28 | 16:43 ET | [8-K](/filings/0001213900-26-104099.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-104099 | | 2026-09-23 | 17:08 ET | [8-K](/filings/0001213900-26-102691.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-102691 | | 2026-09-11 | 16:30 ET | [8-K](/filings/0001213900-26-099294.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-099294 | | 2026-09-04 | 17:25 ET | [8-K](/filings/0001213900-26-097770.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-097770 | | 2026-08-27 | 17:00 ET | [8-K](/filings/0001213900-26-094429.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-094429 | | 2026-08-24 | 17:10 ET | [8-K](/filings/0001213900-26-093122.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-093122 | | 2026-08-17 | 17:05 ET | [10-Q](/filings/0001213900-26-090821.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090821 | | 2026-08-14 | 17:19 ET | [10-Q/A](/filings/0001213900-26-090289.md) | Quarterly report, amended, period 2026-03-31 | 0001213900-26-090289 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-038629.md), filed Apr 1, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1907223 - Tickers: GRML, GRMLW - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 17:30 ET. No prices; not investment advice.